On June 17, 2024 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024 (Press release, CytomX Therapeutics, JUN 17, 2024, View Source [SID1234644382]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "We are excited to announce this promotion, which is a reflection of Chris’ financial acumen, strategic leadership and deep commitment to CytomX’s mission."
Mr. Ogden joined CytomX in August of 2021 as Vice President, Finance and Accounting and has since served in roles of increasing responsibility spanning finance, accounting, investor relations, capital raising, information technology, and facilities, most recently as Senior Vice President, Finance and Accounting. Mr. Ogden joined CytomX after a 16-year tenure at Eli Lilly and Company, where he held senior financial leadership positions, including most recently as chief financial officer of Lilly Diabetes. Prior to his role in Lilly Diabetes, Mr. Ogden was the chief financial officer and treasurer of Lilly del Caribe in Puerto Rico. Over the course of his career at Eli Lilly, Mr. Ogden held financial leadership roles that included drug development, manufacturing, commercial operations, and investor relations. Mr. Ogden received his M.B.A. from Harvard Business School and his B.A. in economics from Wabash College.
"It is a privilege to work with the incredibly talented team at CytomX, and I am thrilled to assume the CFO role and to continue to help lead the company through this next chapter, as we pursue our vision to transform lives with safer, more effective cancer therapies," said Chris Ogden. "CytomX’s pipeline is positioned in some of the most exciting areas of oncology research and development including T-cell engagers and antibody drug conjugates, and our PROBODY platform and business model provides a strong foundation to build significant long-term shareholder value through sustained innovation."